Background: Oculopharyngodistal myopathy (OPDM) has been reported as a rare, adult-onset hereditary muscle disease with putative autosomal dominant and autosomal recessive inheritance. Patients with OPDM present with progressive ocular, pharyngeal, and distal limb muscle involvement. The genetic defect causing OPDM has not been elucidated.
Oculopharyngodistal myopathy (OPDM) is a rare, adult-onset hereditary muscle disease with both autosomal dominant and autosomal recessive inheritance patterns. 1, 2 So far, a total of 29 patients from 14 families presenting a clinical phenotype compatible with the original report have been described worldwide. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Patients with OPDM have been reported to show symmetric ptosis and ophthalmoparesis and to develop swallowing difficulties and distal muscle weakness. 1, 8 Muscle histochemistry shows myopathic changes of different severity with rimmed vacuole formation. 9 The genetic defect causing OPDM has not been identified so far.
We describe our detailed clinical and molecular genetic findings in 47 patients with OPDM from Turkey. The considerable size of the cohort studied and the long-term follow-up enables us to further define the phenotypic characteristics and the temporal course of the condition. Our cohort includes a large spectrum of patients with early and late clinical features of OPDM, as well as patients with atypical presentations.
METHODS Clinical and laboratory findings of 47 patients from 9 unrelated Turkish families diagnosed with OPDM at the Department of Neurology, Istanbul Faculty of Medicine, between 1982 and 2009 were evaluated. Patients who had the clinical phenotype and muscle biopsy findings compatible with the previous reports on OPDM were identified and first-degree family members of the patients showing oculopharyngeal involvement with or without limb weakness were included in the study. After reviewing the records retrospectively, neurologic reexamination of the living patients was performed by 2 of the authors (H.D. and P.S.-O.). Clinical data of 10 other deceased patients were obtained from relatives and clinic charts.
Diagnostic electrophysiologic studies included standard EMG and nerve conduction studies (NCV). Further electrophysiologic studies for the evaluation of swallowing were performed by 2 of the authors (C.E. and M.G.). The degree of dysphagia was compared with the electrophysiologic findings using a previously described grading system. 12 Piecemeal degluti-tion and dysphagia limit assessment using 3, 5, 10, 15, and 20 mL bouts of water and percutaneous EMG on thyroarytenoid (TA) and cricopharyngeal (CP) sphincter muscles were performed. 13 Otolaryngologic examination, including evaluation of vocal cords' alignment and function, voice, articulation, and swallowing, was performed by one of the authors (I.E.).
Skeletal muscle biopsies were performed in at least one index patient from each family. Eight-micrometer sections from shock-frozen tissue samples were stained with hematoxylineosin, modified Gomori trichrome, acid phosphatase, periodic acid-Schiff, NADH dehydrogenase, succinate dehydrogenase, cytochrome c oxidase, and oil red O using standard procedures. Electron microscopy was performed in 3 patients.
Spirometric measurements including forced vital capacity (FVC) in sitting and supine position, forced expiratory volume in 1 second (FEV 1 ), FEV 1 /FVC ratio, and daytime arterial blood gas measurements were performed by one of the coauthors (E.K.). The lips of the patient were manually pressed against the mouthpiece to prevent air leakage if necessary. Echocardiographic and electrocardiographic evaluations were done at different cardiology clinics following standard protocols.
For exclusion of OPMD, at least one patient for each family was analyzed for GCG expansion in exon 1 of the PABPN1 gene. PCR testing essentially followed the published protocol, but used a new reverse primer (3Ͻ ϽTCAGACTCCAGGC-CGTTC). 14 Myotonic dystrophy 1 was excluded by screening the CTG repeat in the 3Ј region of the dystrophia myotonicaprotein kinase (DMPK) gene with triplet repeat primed-PCR. Five patients were analyzed for facioscapulohumeral dystrophy (FSHD) by direct genetic testing using probe p13E-11.
Thirty-six individuals (15 from family 1, 3 from family 2, 5 from family 3, 4 from family 4, 2 from families 5, 6, 7, and 8, and 1 from family 9) were selected and genotyped using the Illumina Infinium II Human Linkage-12 Panel, which includes 6,090 validated SNP markers by GeneService Ltd., Nottingham. We performed multipoint parametric and nonparametric linkage analysis on the largest autosomal dominant (family 1) and autosomal recessive (family 2) families separately and combined with other families using Merlin. 15 Autosomal recessive, autosomal dominant, and codominant disease models were used for the parametric linkage analyses. The linkage was considered as excluded if the lod score was less than Ϫ2 (not shown in table 1).
Standard protocol approvals, registrations, and patient consents.
Written informed consent of all participants (or guardians of patients) was obtained according to the Declaration of Helsinki, and the study was approved by the Ethical Committee of Istanbul University Faculty of Medicine.
RESULTS Clinical findings.
Sixteen patients were women and 31 were men (table 1). Inheritance was compatible with autosomal dominant trait in 5 families with a total of 35 patients (families 1, 3, 4, 6, and 8) and was suggestive of autosomal recessive trait in 1 family (family 2) including 5 patients. The pattern of inheritance could not be determined with confidence in 3 families (families 5, 7, and 9; figure 1). The mean age at onset was 22.1 Ϯ 8.5 years (range, 7-50 years). The mean disease duration was 17.2 Ϯ 12.3 years (range, 1-41 years) at the time of the last examination. The mean follow-up period was 39.4 months (range, 5 months-17 years). The most common initial complaint was droopy eyelids (36/47) (table 1). Forty-six patients had ptosis, which was accompanied with variable degrees of ophthalmoparesis in 39 (table 1) . These were the only symptoms in patients with disease duration less than 5 years. Lateral gaze was usually affected first and most severely. The ptosis was asymmetric in 4 patients and one of them (patient 35) also had asymmetric extremity weakness.
Facial muscle wasting was seen in 36 patients (figure 2, figure e-1 on the Neurology ® Web site at www.neurology.org) with disease duration more than 5 years, the most severely affected being orbicularis oris, malar, and zygomatic muscles. Sternocleidomastoid muscle weakness was not found until advanced stages of the disease.
Thirty-four patients with disease duration more than 5 years showed slowly progressive weakness which initially affected the distal muscles (figure 2). Sixteen of these 34 patients developed proximal muscle involvement during the course of the disease. Three of the 7 patients who were examined at an early stage of the disease showed weakness of finger and toe extensors; 4 (patients 9, 10, 45, and 46) showed mild medial gastrocnemius muscle atrophy and mild tibialis anterior muscle weakness. Four other patients (patients 8, 38, 39, and 41) had clearly dominant proximal weakness with proximal onset, especially in the lower extremities (table 1 and table  e- Swallowing difficulty, which was the major complaint of patients with disease duration more than 5 years, was present in 35, and laryngeal involvement with hoarse and nasal voice in 30 patients. Dysphagia was more pronounced for fluids and 19 patients lost weight in excess of 10 kg during the course of the disease. Three patients (patients 29, 31, and 44) had undergone cricopharyngeal myotomy because of severe progressive dysphagia, without clinical benefit in any. Mild to severe tongue weakness was found in 22 and high palate in 26 patients. Seven of the 13 patients who underwent ENT examination had bowing of the vocal cords. Patients 21 and 45 had sensorineural hearing loss and 3 other patients had reduced hearing (patients 14, 31, and 38).
Ten patients died during the follow-up at a mean age of 44. (table 1) .
All 16 patients who underwent routine electrophysiologic studies revealed normal NCVs, except for patient 41, who had concomitant demyelinating neuropathy, and myogenic motor unit potentials with typical myotonic discharges in both proximal and distal muscles in 8 (table e-2).
Electrophysiologic evaluation of swallowing of 15 patients revealed abnormal dysphagia limit during swallowing of a 3-to 5-mL water bolus in 10 (patients 14, 15, 16, 20, 23, 24, 27, 31, 36, and 39 ). This was interpreted as oral and upper pharyngeal involvement. Needle EMG of TA and CP sphincter muscles was performed in 5 patients with severe dysphagia and showed pure myopathic changes in TA in 4 (patients 14, 15, 31, and 36), with no myotonic discharges in TA and CP sphincter muscles investigated.
Spirometry was performed in 21 patients who were independently ambulant except 3 who were walking with support and one who was wheelchairbound. Clinical and laboratory findings of 13 of them revealed respiratory involvement of differing severity, starting from the sixth year of onset. FEV 1 / FVC ratio was Ն80% in all patients. Mild to moderate (n ϭ 5) (FVC between 50% and 70%) to severe (n ϭ 2) (FVC Ͻ50%) restrictive ventilatory defect was found in 7 patients. Postural drop in FVC of more than 10% indicating diaphragmatic weakness observed in 7 patients ( Skeletal muscle biopsies performed in 12 patients at different stages of the disease revealed myopathic changes with rimmed vacuoles in all (figure 3, A-C). Chronic myopathic changes without any myonecrosis and inflammation were the most consistent finding. Electron microscopy of the muscle biopsy of patients 6, 20, and 42 revealed several autophagic vacuoles containing various multilamellar structures with mixtures of glycogen granules, myelin and fingerprint-like concentric whirled figures, and granular and fibrillar material ( figure 3D ).
Molecular genetic studies. Amplification of exon 1 of PABPN1 to search for GCG expansion to exclude OPMD (at least one patient for each family) and exclusion of locus of PABPN1 gene based on lod scores lower than Ϫ2.0 in linkage analysis (lod score was Ϫ3.7 on autosomal dominant model, Ϫ2.8 on autosomal recessive model) excluded OPMD for all patients tested. All the tested patients showed normal CAG repeats in the DMPK gene excluding DM1. Direct genetic testing using probe p13E-11 excluded FSHD in 5 patients. The genetic loci for all known muscular dystrophies, distal and myofibrillar myopathies (ZNF9, PABPN1, LMNA, SYNE1, SYNE2, MYOT, CAV3, CAPN3, DYSF, SGCG, SGCB, SGCA, SGCD, TCAP, TRIM32, FKRP, TTN, POMT1, POMT2, ANO5, POMGNT1, FKTN, LAMA2, FCMD, LARGE, SEPN1, DNM2, COL6A1, COL6A 2, COL6A 3, ITGA7, PLEC1, GDF8, DYSF, DES, TTN, GNE, MYH7, NEB, ZASP, LDB3, TPM3, TPM2, CRYAB, SEPN1, FLNC, BAG3, ACTA1, TNNT1, CFL2, MTM1, MHY7, CNTN1, LAMP2, DMPK, VCP, MYHC2A, MATR3) were excluded in the largest autosomal dominant and autosomal recessive OPDM families (family 1 and 2) based on lod scores lower than Ϫ2.0. 16
DISCUSSION
Since its acknowledgment as OPDM in 1977, 29 patients from 14 families with a rare, hereditary, adult-onset myopathy having ocular, pharyngeal, and distal extremity involvement were presented in 10 reports from different parts of the world. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Oculopharyngeal muscular dystrophy (OPMD) was genetically excluded in only 7 of these families. [7] [8] [9] 11 Here we report the largest series of 47 patients with OPDM from Turkey. In our OPDM families, DM1, FSHD, and OPMD were excluded genetically by direct testing. Furthermore, linkage analysis convincingly excluded chromosomal loci for all known adult-onset muscle disorders with ocular or distal involvement in our largest putative autosomal dominant and autosomal recessive families. 16 The mean age at onset in our group was slightly earlier than in the published series. This may be due to a different genetic defect causing OPDM phenotype in the Turkish patients. Alternatively, multigenerational knowledge about the condition in the Turkish families may have led to early recognition by patients and relatives. In our largest OPDM family (family 1) with 19 affected patients, symptoms became apparent 10 years earlier in the 3rd generation than in the 2nd generation. Significant variation in the age at onset, severity, and distribution of weakness among the affected close relatives in this family may suggest anticipation (table 2) .
Both autosomal dominant and autosomal recessive inheritance patterns were present in our families. Thirty-six (families 1, 3, 4, 6, and 8) of the 47 patients came from Kastamonu, a town located in the northwest of Turkey, whereas the other families originated from different regions of the country. Notably, all OPDM families from Kastamonu were compatible with autosomal dominant inheritance. Patients from autosomal dominant and autosomal recessive families did not show a significant difference for age at onset, clinical presentation, disease severity, or laboratory findings. Despite these similarities, different causative genes and coincidental occurrence of various mutations need to be considered based on the different inheritance patterns. Different repeat size in trinucleotide repeat disorders could also cause both seemingly autosomal dominant and autosomal recessive inheritance patterns. In addition to an autosomal recessive inheritance, other mecha-nisms such as germline mosaicism or a premutation in one of the parents may also be considered in family 2. The inheritance pattern might be autosomal recessive in families 5, 7, and 9, but X-linked inheritance cannot be fully ruled out in some of the smaller families.
Although ptosis was the most frequent initial symptom, in agreement with previous studies, prominent facial muscle atrophy was the most stigmatizing finding. Previously unreported findings, such as mild to moderate asymmetric ptosis in 4 of our patients with asymmetric extremity weakness in one, and the presence of prominent proximal weakness in 4 other patients, widen the clinical spectrum of OPDM.
Oropharyngeal dysphagia of myopathic origin was one of the most prominent features of the condition. Experience in interventional procedures such as cricopharyngeal myotomy in OPDM is limited. As 3 of our patients who had undergone this procedure experienced worsening in swallowing thereafter, it is recommended to be used with caution. Physiotherapeutic conditioning of the buccal and pharyngeal muscles and percutaneous endoscopic gastrostomy placement in patients with weight loss or frequent aspiration should be considered early in the course of the disease.
Seven of the 13 patients who underwent ENT examination had bowing of vocal cords, which refers to the existence of a gap between the vocal cords during phonation that is caused by loss of vocal cord volume. Disproportional bowing without impairment of mobility of vocal cords might have contributed to hoarseness, dysphagia predominantly with fluids, and aspiration. Five of our patients had hearing loss, 2 of whom had findings of sensorineural hearing loss, suggesting that sensorineural hearing loss may be a feature of the disease.
Respiratory muscle involvement has previously been reported in 4 patients with OPDM. 4, 6, 9 Although respiratory involvement is a common finding in the late stage of several myopathies, early respiratory involvement is relatively rare. [17] [18] [19] Early respiratory involvement while the patients were still ambulant was a frequent finding in our patients. Respiratory complications were also frequent and major causes of death in our cohort. Early and regular assessment of respiratory function is therefore highly recommended. Noninvasive positive pressure ventilation should be advocated for treating nocturnal hypoventilation and respiratory failure, and for preventing secondary complications such as pneumonia.
Eight of the 16 patients who underwent routine EMG had typical myotonic discharges without any clinical sign or symptom of myotonia (table 1) . Myo-tonic discharges in OPDM have rarely been reported by others.
Rimmed vacuoles could be found in several myopathies. 20 -22 The electron microscopy analysis in 3 of our patients revealed autophagic vacuoles and degradation products ( figure 3B ), but did not show any tubular filamentous inclusions as OPMD.
The attempt to group the clinical findings in our cohort at 5-year intervals of disease duration at last visit clearly shows that while there were no other symptoms than ptosis and ophthalmoparesis in the first 5 years, facial atrophy, swallowing and speech difficulties, and extremity weakness became apparent between 5 and 10 years after onset and gradually worsened thereafter. Respiratory involvement was found in patients as early as the sixth disease year. Therefore, the term "oculopharyngodistal myopathy" may be a rather incomplete description of the condition. Faciooculolaryngopharyngeal myopathy with distal and respiratory involvement, or FOLP-DR, may be a more accurate and descriptive term.
As the genetic defect underlying OPDM is not known, the diagnosis currently rests upon clinical and histopathologic features, and on the genetic exclusion of similar conditions, namely OPMD, DM1, FSHD, and distal myopathies.
There is clinical overlap between OPDM and OPMD as both diseases have similar distribution of weakness and histopathologic features. However, onset after 40 years of age is atypical in OPDM. Although both diseases present with progressive ptosis, findings such as limitation of eye movements, facial weakness, distal wasting, and weakness are typical for OPDM, whereas they are not features of OPMD. [22] [23] [24] [25] Differential diagnosis with DM1, which has involvement of facial and distal limb muscles, together with the presence of electrophysiologic myotonia, and with FSHD, which presents with facial atrophy in a young adult patient, may be difficult. 26 However, marked ophthalmoparesis is not a feature of any of these diseases and lower facial atrophy in OPDM does not resemble that in FSHD. 27 Similarly, the diagnostic dilemma caused by the distal weakness and wasting present both in the majority of patients with OPDM and in other distal myopathies with rimmed vacuoles may be eliminated by considering the prominent ocular, facial, and pharyngeal involvement in OPDM.
The present study with an unprecedented number and long follow-up of patients with OPDM allowed us to refine the clinical phenotype of OPDM, to propose a more descriptive name for the condition, and to pave the way to identify the genetic defect.
